METHOD FOR PREDICTING EFFICACY OF IMMUNE CHECKPOINT INHIBITOR ON TEST SUBJECT

WIPO Patent Application WO/2018/190379

A1

This method for predicting efficacy of an immune checkpoint inhibitor on a test subject comprises: (a) a step for collecting cells from a blood sample of a test subject; (b1) a step for bringing the cells into contact with a primary antibody capable of recognizing PD-L1 and further bringing the cells into contact with a secondary antibody which is capable of recognizing the primary antibody and which is labeled with a fluorescent dye, or a step for bringing the cells into contact with an antibody capable of recognizing PD-L1 and labeled with a fluorescent dye; and (c) a step for irradiating the cells with excitation light for the fluorescent dye so as to detect fluorescence emitted from the cells, wherein in the case when the cells are PD-L1-positive cancer cells, the immune checkpoint inhibitor is determined to have high efficacy on the test subject. Thus the present invention is configured to enable predicting efficacy of an immune checkpoint inhibitor without imposing too much burden on a test subject.

WO/1993/022331	HUMAN CRABP-I AND CRABP-II
WO/2015/031645	MONOCLONAL ANTIBODIES TO HUMAN 14-3-3 EPSILON AND HUMAN 14-3-3 EPSILON SV
WO/2016/004221	METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS RESISTANT TO PROTEASOME INHIBITOR TREATMENTS

YAGI SATOMI (JP)
ENDOU KATSUYA (JP)
HIGUCHI MASAYUKI (JP)
KANBARA HISASHIGE (JP)
KOH YASUHIRO (JP)
YAMAMOTO NOBUYUKI (JP)
AKAMATSU HIROAKI (JP)

PCT/JP2018/015264

October 18, 2018

April 11, 2018

Click for automatic bibliography generation  

HITACHI CHEMICAL CO LTD (JP)
WAKAYAMA MEDICAL UNIV (JP)

G01N33/53; G01N33/48; G01N33/543; G01N33/574

WO2016035772A1	2016-03-10
WO2015174539A1	2015-11-19
WO2018029858A1	2018-02-15

JP2011163830A	2011-08-25
JP2016086736A	2016-05-23
KR20180048215A	2018-05-10

KO, YASUHIRO: "Measurement of PD-L1 expression in circulating- tumour cell with respect to ongoing lung cancer", METHODS, CONCLUSION, NON-OFFICIAL TRANSLATION, vol. 14, pages 2 - 145
KO, YASUHIRO: "Circulating tumor cells and their PD-L1 expression", JOURNAL OF MOLECULAR TARGETED THERAPY FOR CANCER, vol. 14, no. 2, 8 July 2016 (2016-07-08), pages 228 - 232
"Diachronic analysis on PD-L1 positive circulating-tumor cells in blood with respect to non-small cell lung cancer patient who received nivolumab therapy", PROCEEDINGS OF THE JAPANESE LUNG CANCER SOCIETY, vol. 57, no. 5, 5 September 2017 (2017-09-05), pages 607 , P 57 - 5
TANAKA, AYAKA: "Evaluation of a novel automated device for size-based enrichment and isolation of CTCs in patients with advanced lung cancer", ANNALS OF THE JAPANESE RESPIRATORY SOCIETY, vol. 5, 2016
KIM, WOONG: "Differential expression of PD-L1 on circulating tumor cells among patients with advanced lung cancer", CANCER RESEARCH, vol. 76, no. 14, July 2016 (2016-07-01), pages 2257
PANIEL, KLAUS: "Circulating tumor cells: Detection, Biology and Clinical Implications", PROGRAM ABSTRACTS OF MEETING OF THE JAPANESE ASSOCIATION FOR METASTASIS RESEARCH, vol. 26, 2017, pages 62
KANBAYASHI, SATOSHI: "Review on PD-L1 expression in circulating-tumour cell with respect to lung cancer", PROCEEDINGS OF THE JAPANESE LUNG CANCER SOCIETY, vol. 56, no. 6, 5 November 2016 (2016-11-05), pages 802
"Diachronic analysis on PD-L1 positive circulating-tumor cells in blood with respect to non-small cell lung cancer patient who received nivolumab therapy", THE JOURNAL OF THE WAKAYAMA MEDICAL SOCIETY, vol. 69, no. 1, 31 March 2018 (2018-03-31), pages 74 - 75

HASEGAWA Yoshiki et al. (JP)

View/Download PDF      PDF Help

Previous Patent: RHAMNOSE SYNTHASE DERIVED FROM STEVIA AND GENE

Next Patent: MULTILEVELED SUBSTRATE COATING FILM FORMING COMPOSITION CONTAINING PLASMA-CURABLE COMPOUND BASED ON ...